Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TWST vs EDIT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TWST Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–2 Matrix Metrics)

TWST Overall Winner 6-Pillar Tally: TWST 4 – 2 EDIT Matrix Metrics: TWST 6 – 2 EDIT

As of Nov 16, 2026, Twist Bioscience Corporation (TWST) is the stronger overall head-to-head candidate over Editas Medicine, Inc. (EDIT) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). TWST carries a Unified Composite Score of 51.7/100 (HOLD) at $105.85 (N/M Forward P/E, -31.9% operating margin), whereas EDIT carries 48.4/100 (HOLD) at $1.91 (N/M Forward P/E, -167.0% operating margin).

  • Technical & Structure Timing Caution: TWST trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 36.1); meanwhile EDIT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TWST vs EDIT
TWST NASDAQ Head-to-Head Winner
Twist Bioscience Corporation Common Stock
Biological Products, (No Disgnostic Substances)
$105.85
-5.15% 1D
Market Cap $7.6B
TTM Revenue $432M
Forward P/E N/M
Beta / 30D Vol 3.15β · 127% Vol
Unified Composite Score
51.7 / 100 HOLD
Tech 40.0 Fund 56.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 36
RSI-14: 36.1 · SMA20: $137.35 · SMA50: $149.85
EDIT NASDAQ
Editas Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.91
-12.21% 1D
Market Cap $336.5M
TTM Revenue $50M
Forward P/E N/M
Beta / 30D Vol 2.32β · 102% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 33.0 Fund 55.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.3%), weak momentum, RSI 33
RSI-14: 33.4 · SMA20: $2.52 · SMA50: $2.61

6-Pillar Scorecard Institutional Category Breakdown (TWST 4 – 2 EDIT)

Columns: Metric · TWST · EDIT
1. Valuation Multiples EDIT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 17.5x 5.2x
2. Growth & Scale TWST
Revenue Growth (YoY) +23.2% +37.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $432M $50M
Market Cap $7.6B $336.5M
3. Profitability & Quality TWST
Gross Margin 52.0% -73.3%
Operating Margin -31.9% -167.0%
Net Profit Margin -31.7% -144.9%
Return on Equity (ROE) -29.6% -147.4%
4. Balance Sheet & Cash Flow TWST
Cash Generation (TTM) -$115M EBITDA -$110M
Cash Flow Margin -26.7% EBITDA Mgn N/A
Net Cash / Leverage $7.11 Book/Sh · -29.6% ROE $79M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EDIT
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 93.2% (18th %ile) 95.8% (38th %ile)
Put/Call OI Skew 1.04x (Balanced) 0.29x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat TWST
OpEx & R&D Intensity 83.9% of Rev ($362M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Concentrated Oligopoly Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TWST (6) vs EDIT (2)
Institutional Metric TWST EDIT Criterion Row Edge
Market Capitalization
Scale
$7.6B $336.5M Larger Scale TWST
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+23.2% +37.4% Higher Growth EDIT
Operating Margin (TTM)
Profitability
-31.9% -167.0% Higher Margin TWST
Net Profit Margin
Profitability
-31.7% -144.9% Higher Margin TWST
Return on Equity (ROE)
Capital Efficiency
-29.6% -147.4% Higher ROE TWST
52-Week Range Position
Momentum
42% ($23–$220) 11% ($2–$4) Stronger Trend TWST
Beta / 30D Volatility
Risk Regime
3.15β · 127% Vol 2.32β · 102% Vol Lower Realized Risk EDIT
Unified Institutional Score
Composite Signal
51.7 / 100 (HOLD) 48.4 / 100 (HOLD) Higher Composite TWST
Trailing 12M Revenue (USD)
Operating Scale
$432M $50M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
52.0% -73.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 17.5x EV/Rev N/M PEG · 5.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$115M EBITDA ($7.11 Book/Sh · -29.6% ROE) -$110M ($79M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EDIT +1.32 pp
TWST: -20.26% · EDIT: -18.94%
3M Horizon TWST +25.02 pp
TWST: -8.83% · EDIT: -33.85%
6M Horizon TWST +137.29 pp
TWST: +112.59% · EDIT: -24.7%
1Y Horizon TWST +279.01 pp
TWST: +254.01% · EDIT: -25.0%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period TWST Revenue EDIT Revenue TWST Op. Margin EDIT Op. Margin Margin Leader
FY2018 $30M $30M -277.5% -356.1% TWST
FY2019 $50M $20M -200.1% -686.4% TWST
FY2020 $90M $90M -155.5% -148.6% EDIT
FY2021 $130M $30M -115.4% -756.1% TWST
FY2022 $200M $20M -115.3% -1146.3% TWST
FY2023 $250M $80M -88.6% -216.6% TWST
FY2024 $310M $30M -70.6% -777.2% TWST
FY2025 $380M $40M -36.2% -394.9% TWST

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TWST CONSOLIDATION
69d in phase · OBV DISTRIBUTION
Current IV 93.2%
IV Percentile 18th %ile
Put/Call OI Skew 1.04x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact TWST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EDIT BREAKDOWN
146d in phase · OBV NEUTRAL
Current IV 95.8%
IV Percentile 38th %ile
Put/Call OI Skew 0.29x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EDIT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TWST Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.6B market capitalization and -31.9% operating margin.
OpEx & R&D Reinvestment 83.9% of Rev ($362M)
90D Engineering Disclosures 0 Published · Spatial Genomics
EDIT Moat Profile Concentrated Oligopoly Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $336.5M market capitalization and -167.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing

Investor FAQ TWST vs EDIT Key Questions & Quantitative Answers

As of Nov 16, 2026, Twist Bioscience Corporation (TWST) is the stronger overall head-to-head candidate over Editas Medicine, Inc. (EDIT) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). TWST carries a Unified Composite Score of 51.7/100 (HOLD) at $105.85 (N/M Forward P/E, -31.9% operating margin), whereas EDIT carries 48.4/100 (HOLD) at $1.91 (N/M Forward P/E, -167.0% operating margin). Technical & Structure Timing Caution: TWST trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 36.1); meanwhile EDIT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TWST leads the Growth & Scale pillar: TWST posts +23.2% YoY revenue growth and +0.0% YoY earnings growth on $432M TTM revenue (52.0% gross margin, -31.9% operating margin), compared with EDIT at +37.4% YoY revenue growth and +0.0% YoY earnings growth on $50M TTM revenue (-73.3% gross margin, -167.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), TWST cumulative revenue shifted +1166.7% while EDIT shifted +33.3%. In operating R&D and SG&A reinvestment, TWST deploys 83.9% of Rev ($362M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EDIT.

EDIT screens cheaper on headline valuation multiples. TWST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 17.5x EV/Revenue (-26.7% EBITDA margin), whereas EDIT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 5.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TWST (-29.6% ROE) versus EDIT (-147.4% ROE) capital efficiency.

In options market volatility and institutional positioning, TWST carries 93.2% implied volatility (18th %ile, Compressed (<25th %ile)), a 1.04x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (3.15β · 127% Vol realized risk). By comparison, EDIT carries 95.8% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.29x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.32β · 102% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.